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Introduction
Drug and alcohol use can lead to numerous undesirable so-cial, psychological, and physical consequences.1–3 How-
ever, due to the association between addiction and other 
factors, such as risky behaviors (e.g., unsafe sex and drug injec-
tion), different types of cancer, and cardiovascular diseases, as 
well as impaired driving behaviors, more attention needs to be 
paid to drug and alcohol dependents as one of the most important 
health risk target populations around the globe.4–6 
Its shared borders with Afghanistan and Pakistan make Iran 
one ofWKHPDLQURXWHVIRUJOREDOGUXJWUDI¿FNLQJ7KLVSUR[LP-
ity creates easy drug accessibility and has resulted in a consider-
able number of drug users in the country.7 Increasing illicit drug 
use in new forms in recent years8 and the higher possibility of 
engaging in high-risk sexual and injection-related behaviors has 
led to a higher prevalence of major infectious diseases (e.g., HIV/
AIDS and different types of viral hepatitis) among drug users, and 
especially among intravenous drug users.6,9,10 This may partly ex-
plain the great burden of illicit drug abuse imposed on the Iranian 
healthcare system.
Due to the existing socio-cultural setting in the country, alcohol 
use is banned in Iran. Therefore, not surprisingly, access to data 
regarding this issue is limited. One of the few existing reports—a 
population-based cross sectional study conducted in 2010—dem-
onstrated that the prevalence of alcohol use among Iranian ado-
lescents is about 15%.11 In another study, results of alcohol and 
drug assessment tests were positive among 20% of Iranian drivers 
NLOOHGLQWUDI¿FDFFLGHQWVEHWZHHQDQG12 Results from 
another study among a group of students in a medical university in 
Iran showed a 9% alcohol consumption over six months in 2001.13 
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These studies shed light on the fact that alcohol use is hidden, but 
is still a major public health problem in Iran. 
Recently, the Institute for Health Metrics and Evaluation (IHME) 
has conducted a comprehensive systematic review to calculate the 
Global Burden of Disease study (the GBD study 2010) and has 
provided the results for the years 1990, 2005, 2010, and published 
the results in 2013.14 The aim of the present study is to report the 
burdens of drug and alcohol use disorders in Iran according to the 
GBD study 2010 results. The data will be provided in terms of 
disability-adjusted life years (DALYs), years of life lost to prema-
ture mortality (YLLs), and years lived with disability (YLDs). In 
addition, we will discuss some limitations of the GBD study 2010 
and provide some recommendations for promoting the estimation 
of the burden of drug and alcohol use disorders in Iran. 
Materials and Methods
Components of data, data quality, and statistical models for the 
GBD Study 2010 estimation are described in detail elsewhere.15–21 
The basic objective of the GBD Study 2010 comparative risk as-
sessment was to compute the proportion of deaths or disease bur-
GHQFDXVHGE\VSHFL¿FULVNfactors. In the present study, for the 
¿UVWWLPHLQIran, we provide a summary of drug and alcohol use 
GLVRUGHUVDQGVSHFL¿FPHWKRGVXWLOL]HGLQWKH*%'6WXG\to 
derive the attributed risk factors. 
The global estimation of disease burden attributed to drug and 
alcohol use disorders had ¿YHVWHSV7KH¿UVWVWHSZDVWRVHOHFW
risk-outcome pairs to be included in the analysis, based on causal 
association criteria. The distributions of exposure to each risk 
factor in the population were estimated during the next step. A 
systematic review was conducted from 1990 to 2010, identify-
ing published and unpublished data sources in order to estimate 
the distribution of risk factor exposure. At the end of this stage, a 
mixed effects regression method22 was used for estimating alcohol 
use and DisMod-MR version 3 was used to estimate drug use. The 
third step was to estimate etiological effect sizes, which is often a 
relative risk per unit of exposure for each risk-outcome pair. The 
proportional reduction in diseases that lead to certain death, after 
a reduction in risk factor exposure level, was computed for each 
risk factor and disease causally linked with its exposure, known 
as the population attributable fraction (PAF). The next stage was 
to choose a counterfactual exposure distribution for comparison 
with the current exposure distribution. The global team was se-
lected with an optimum exposure distribution and termed the 
theoretical-minimum-risk exposure distribution for this purpose. 
No alcohol consumption and non-use of cannabis, opioid, or am-
phetamines and non-use of injected drugs were the counterfac-
tual exposure distributions for alcohol and drug use, respectively. 
The last step for risk assessment was calculation of the burden of 
deaths and diseases attributed to each risk factor including uncer-
tainty from all sources. Published studies23,24 were included for 
alcohol use, while new meta-analyses as well as published stud-
ies25,26 were included for drug use; these were used for the calcu-
lations of the burdens of the risk factors. Figures were prepared 
using R software for windows. The entire measures have been 
reported with a 95% Uncertainty Interval (UI).
In the present paper, we extracted data related to the burdens of 
drug and alcohol use disorders in Iran based on the GBD Study 
2010, analyzed and reformulated data, drew new graphs, and cri-
tiqued the results. 
Results
The highest death rates (deaths per 100,000 individuals) due to 
drug use disorders among men were related to those aged 70 and 
higher, which was 6.3 [95% UI: 1.5–14.8] in 1990 and increased 
to 15.5 [6.4–39.5] in 2010. Similarly, death rates were higher 
among female drug users in the same age groupsat0.97 [0.3–2.4] 
per 100,000 in 1990, and 0.62 [0.37–1.2] in 2010. Compared 
to the other age groups, alcohol-related deaths were also higher 
among men 70 years old and higher (0.66 [0.19–1.67] and 0.99 
[0.29–2.68]), and women (0.07 [0.01–0.24] and 0.09 [0.03–0.2]) 
in 1990 and 2010, respectively (Table 1 and Figure 1).
An increasing trend was evident from 1990 to 2010, with the 
highest rates of YLDs related to drug and alcohol use among both 
genders found among people between 15 and 49 years old. Rates 
of YLLs due to alcohol use disorders were higher among people 
aged 50 to 69 and showed a slight increase from 1990 to 2010. 
Drug-related YLLs were also higher among people between 
ages15 and 49 and these rates increased during the years of the 
study (Figure 2). 
Total DALY rate (per 100,000 population) was higher among 
drug user men between 15 to 49 years old in 1990 (858.7[505.1–
1467.1]), rose to 1199.7 [730–1995] in 2010. Drug-related DALYs 
were also higher among women in the same age group in 1990 
(291.6 [171.5–466.4]) which increased to 342.5 [190.5–573.7] in 
2010. Similar to the drug use disorders, alcohol-related DALYs 
were higher among men (151[78.4–266.4] and 152.6[78.1–
267.9]) and women (33.2[17–57.5] and 33.4[17.2–57.3]) aged 15 
to 49, in 1990 and 2010, respectively (Table 2 and Figure 3).
The number of DALYs due to drug disorders among men for 
all ages was 110605 in 1990, which increased dramatically over 
the time, ultimately reaching 301996 in 2010. These numbers 
among women were 37,626 and 82,689, respectively. The num-
ber of deaths among men for all ages attributed to drugs was 819 
in 1990 and increased to 2912 in 2010. For women, the numbers 
were 47 and 226, respectively. The number of DALYs related to 
men for all ages due to alcohol use in 1990 and 2010 were 21947 
and 41917, respectively. The numbers of DALYs for women were 
5020 and 9005, respectively. The number of deaths among men 
for all ages attributed to alcohol use was 27 in 1990, which in-
creased over time to reach 61 in 2010. For women, these numbers 
were 5 and 10, respectively. 
Discussion
Drug-related measures for all ages, including rates of YLLs, 
YLDs, and DALYs, were higher among Iranian men than women 
in 2010. Similarly, worldwide results from the GBD Study 2010 
demonstrated higher rates of YLLs, YLDs, and DALY among drug 
user men than women.27 These numbers suggest that the burden of 
drug use disorders in Iran follows a similar pattern to the global 
burden of illicit drug use disorders, and higher rates of measures 
among Iranian males are not particularly surprising. Nevertheless, 
more studies should be conducted in Iran to measure the burden 
of drug and alcohol use in different sub-populations. These types 
of studies could contribute to the design and implementation of 
VSHFL¿FWUHDWPHQWDQGSUHYHQWLRQSURJUDPVto reduce the disease 
burden due to drugs and alcohol use. 
%DVHGRQWKH¿QGLQJVLQWKHUDWHVRIobtained measures, 
including YLLs, YLDs, and DALYs, were considerably higher 
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$JH<HDUV 1990 1995 2000 2005 2010
Drug Use
Males
 Under 5 0.44[0.12–1.3] 0.43[0.15–1.1] 0.5[0.2–1.4] 0.68[0.27–1.7] 0.79[0.31–2.1]
 5 to 14 0.03[0–0.1] 0.04[0–0.1] 0.04[0.01–0.1] 0.05[0.02–0.1] 0.05[0.01–0.14]
 15 to 49 5.3[1.5–13.3] 6.45[1.97–13.6] 7.5[2.5–12.9] 8.04[3.2–14.2] 9.4[4–20.8]
 50 to 69 5.5[1.3–14] 7.2[1.9–14.6] 8.9[2.7–15.6] 9.11[3.6–18.3] 11.2[4.6–29.8]
 >70 6.3[1.5–14.8] 8.1[2.1–17.4] 10.4[3.3–20.3] 11.8[4.4–26.2] 15.5[6.4–39.5]
 All ages 2.9[0.86–7.1] 3.8[1.2–7.5] 5.1[1.8–8.6] 6.2[2.6–11.9] 7.7[3.6–17.5]
 Age St. 4.6[1.4–10.9] 5.9[1.8–11.2] 6.9[2.5–11.6] 7.05[2.9–13.2] 7.9[3.8–18.9]
Females 
 Under 5 0.22[0.03–1.3] 0.21[0.05–1.1] 0.26[0.08–1.2] 0.37[0.12–1.6] 0.44[0.12–1.9]
 5 t0 14 0[0–0.01] 0[0–0.01] 0[0–0.01] 0.01[0–0.02] 0.01[0–0.03]
 15 to 49 0.19[0.06–0.4] 0.25[0.09–0.57] 0.33[0.15–0.58] 0.39[0.22–0.75] 0.51[0.25–1]
 50 to 69 0.36[0.12–0.9] 0.49[0.18–1.1] 0.67[0.29–1.1] 0.81[0.37–1.5] 1.1[0.52–2.3]
 >70 0.97[0.3–2.4] 1.2[0.49–2.8] 1.83[0.76–3.2] 2.54[1.17–4.7] 3.8[1.8–7.7]
 All ages 0.17[0.06–0.48] 0.22[0.09–0.44] 0.31[0.15–0.54] 0.43[0.25–0.82] 0.62[0.37–1.2]
 Age St. 0.26[0.09–0.6] 0.33[0.14–0.68] 0.45[0.22–0.77] 0.55[0.32–1.1] 0.72[0.43–1.4]
Alcohol Use
Males
 Under 5 0[0–0] 0[0–0] 0[0–0] 0[0–0] 0[0–0]
 5 t0 14 0[0–0] 0[0–0] 0[0–0] 0[0–0] 0[0–0]
 15 to 49 0.12[0.03–0.35] 0.13[0.05–0.34] 0.14[0.06–0.3] 0.13[0.05–0.31] 0.13[0.05–0.26]
 50 to 69 0.37[0.07–1.39] 0.43[0.12–1.43] 0.45[0.15–1.27] 0.4[0.15–1.11] 0.37[0.14–1.01]
 >70 0.66[0.19–1.67] 0.86[0.27–2.19] 1.05[0.32–2.65] 0.95[0.3–2.34] 0.99[0.29–2.68]
 All ages 0.09[0.03–0.3] 0.11[0.05–0.31] 0.14[0.06–0.29] 0.15[0.07–0.32] 0.16[0.07–0.3]
 Age St. 0.17[0.05–0.52] 0.2[0.08–0.52] 0.21[0.1–0.46] 0.2[0.1–0.42] 0.19[0.09–0.37]
Females 
 Under 5 0[0–0] 0[0–0] 0[0–0] 0[0–0] 0[0–0]
 5 t0 14 0[0–0] 0[0–0] 0[0–0] 0[0–0] 0[0–0]
 15 to 49 0.02[0–0.05] 0.02[0–0.06] 0.03[0–0.08] 0.02[0–0.06] 0.02[0–0.06]
 50 to 69 0.06[0.01–0.2] 0.07[0.02–0.2] 0.08[0.02–0.2] 0.07[0.02–0.17] 0.06[0.02–0.16]
 >70 0.07[0.01–0.24] 0.07[0.02–0.22] 0.09[0.03–0.21] 0.09[0.03–0.21] 0.09[0.03–0.2]
 All ages 0.01[0–0.04] 0.02[0–0.04] 0.02[0–0.05] 0.02[0–0.05] 0.02[0–0.05]
 Age St. 0.03[0.01–0.07] 0.03[0.01–0.07] 0.03[0.01–0.08] 0.03[0.01–0.07] 0.03[0–0.06]
Table 1. 'HDWK5DWHV3HU$WWULEXWHGWR'UXJDQG$OFRKRO8VH'LVRUGHUV
Figure 1. Trend of Deaths and DALYs Rates per 100,000  from 1990 to 2010  by Sex.
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Figure 2.  DALYs rates per 100,000 by Age Group, YLLs, and YLDs.
                $JH<HDUV 1990 1995 2000 2005 2010
Drug Use 
Males
 Under 5 38.1[11.1–113.7] 37.1[12.8–94.9] 43.4[17.8–124.7] 58.4[23.7–146.8] 68.2[27.3–180.3]
 5 t0 14 9.7[3.5–20.6] 10.9[4.1–23.1] 12.2[4.5–25.7] 14.1[5.8–29.2] 13.1[5.7–26.1]
 15 to 49 858.7[505.1–1467.1] 932.9[566.6–1542] 1004.3[621.9–1602] 1055.5[678.6–1611] 1199.7[730–1995]
 50 to 69 249.1[113.5–525.3] 301.4[133.3–549.9] 356.9[171–601.4] 373.2[196.6–662.9] 445.4[224.6–1040]
 >70 87.9[27.9–194.4] 109.5[34.9–224.4] 129.6[48.4–235.8] 141.7[57.5–296.4] 172.7[78.5–403.9]
 All ages 399.6[241.2–675.5] 476.6[291. –779.6] 578.1[360.1–912.1] 682.8[440.9–1037.5] 804.5[497.1–1351]
 Age St. 516.3[304.1–880.6] 572.4[339.4–944.5] 626.7[380.1–968.3] 641.5[412.5-978.2] 691.7[432.4–1161]
Females 
 Under 5 19.1[3.3–117.7] 18.4[4.5–90.9] 22.6[6.8–101.2] 31.5[10.7–134.9] 37.6[10.8–162]
 5 t0 14 4.79[1.1–10.9] 5.3[1.3–12.3] 6.1[1.5–14] 7.2[2–16.6] 6.7[1.9–15.7]
 15 to 49 291.6[171.5–466.4] 299.4[177.1–477.6] 308.3[184.8–491.8] 316.7[184.3–508.4] 342.5[190.5–573.7]
 50 to 69 47.5[26.3–79.1] 53.1[30–86.6] 60.7[35.7–95.9] 67.2[41.7–104.1] 77.8[45.1–129.7]
 >70 14.89[6.47–32.81] 18.44[8.22–38.59] 24.6[11.23–40.82] 31.47[16.1–55.9] 43[21.69–83.09]
 All ages 138.5[81.5–221.7] 156.1[92.3–246.1] 177.9[107.6–278.6] 203.1[120.3–324.1] 227[128.5–376.9]
 Age St. 157.2[92.9–248.7] 162.8[96.9–256.3] 170[103.3–266.7] 176.8[106.9–282.3] 185.3[106.5–305.9]
Alcohol Use 
Males
 Under 5 2.7[0.9–5.8] 2.4[0.8–5.2] 2.2[0.7–4.7] 2[0.5–4.3] 1.9[0.5–4.1]
 5 t0 14 10.4[5.2–18.6] 11.3[5.7–20.1] 12.2[6.1–21.7] 13.2[5.9-24.5] 11.8[5.2–21.4]
 15 to 49 151[78.4–266.4] 150.8[78.6–266.5] 150.1[77.9–263.4] 149[78.7–268.8] 152.6[78.1–267.9]
 50 to 69 115.1[57.4–202.6] 117.8[60.6–206.8] 119.5[62.4–208.9] 119.6[62.1–210.3] 122.1[64.4–208.2]
 >70 43.7[22–75.5] 46[23.6–77.8] 47.7[26.1–82.7] 45.8[24.8–78.1] 44.8[23.6–77.4]
 All ages 79.3[41.3–138.5] 87.3[46.1–151.8] 96.1[50.7–166.4] 105.3[55.4–188.2] 111.7[57.7–193.3]
 Age St. 104.4[53.8–182.9] 104.5[54.6–181.7] 104.2[54.2–180.8] 103[54.8–183.1] 103.5[54.2–178.8]
Females 
 Under 5 1.8[0.5–4.2] 1.7[0.4–3.9] 1.6[0.4–3.6] 1.4[0.3–3.2] 1.5[0.3–3.4]
 5 t0 14 3.5[1.3–6.4] 3.6[1.4–6.6] 3.7[1.4–6.9] 3.9[1.4–7.5] 3.5[1.2–6.3]
 15 to 49 33.2[17–57.5] 33.4[17.3–57.7] 33.4[17.5–57.6] 33.2[17.4–56.7] 33.4[17.2–57.3]
 50 to 69 25.6[12.9–45.9] 25.9[13.1–46.4] 26.2[13.1–46.8] 26.1[13.2–46] 26.2[13.5–46.2]
 >70 8.4[3.7–15] 8.4[3.8–14.9] 8.4[4–15] 8.3[4.1–14.6] 8.1[3.9–14.4]
 All ages 18.5[9.8–31.4] 20.2[10.8–34.1] 22[11.9–37.1] 23.8[12.9–40.3] 24.7[13.1–41.9]
 Age St. 23.2[12.1–39.5] 23.2[12.4–39.2] 23.2[12.5–39.3] 23[12.3–38.5] 22.7[12.2–38.1]
 All ages 18.5[9.8–31.4] 20.2[10.8–34.1] 22[11.9–37.1] 23.8[12.9–40.3] 24.7[13.1–41.9]
 Age St. 23.2[12.1–39.5] 23.2[12.4–39.2] 23.2[12.5–39.3] 23[12.3–38.5] 22.7[12.2–38.1]
Table 2.'$/<5DWHV3HU$WWULEXWHGWR'UXJDQG$OFRKRO8VHGLVRUGHUV
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for alcohol dependent men than for women, similar to the illicit 
drug dependence burden in Iran and in the world. Although results 
from the GBD Study 2010 demonstrate higher DALYs for men, 
the difference between different countries is very slight.28 This in-
consistency might be due to the different patterns of alcohol use, 
which are caused by different socio-cultural norms among com-
munities around the world. Alcohol use still has a hidden pattern 
in Iran. Further studies on alcohol use in this country would likely 
reveal more alcohol-related burdens for women. However, based 
on the GBD study 2010, all DALY, YLL, and YLD rates were 
much higher for drug use, globally as well as in Iran. 
As we mentioned earlier, drug and alcohol use disorders account 
for about 2% of the total burden of diseases in Iran. According to 
WKHZRUOGGUXJUHSRUWRIWKH8QLWHG1DWLRQV2I¿FHRQDrugs and 
Crime (UNODC), Iran is one of the countries with the highest 
level of cannabis, heroin, and methamphetamine seizures.30 This 
issue demonstrates the existence and easy accessibility of these 
GUXJVLQ,UDQDQGUHÀHFWVWKHH[FHVVLYHDPRXQWRIdrug use in this 
country. The considerable rate of drug use in Iran is one of the 
parameters that explains the heavy burden imposed by illicit drugs 
on the healthcare system of Iran. Therefore, drug use preven-
tion education is immediately required and preventive measures 
should be implemented to decrease the burden of drug and alcohol 
use disorders in Iran. 
The GBD Study 2010 is a valuable study but has some limita-
tions in calculating the burden of drug and alcohol use in Iran. The 
scarcity of reliable data sources for drug and alcohol use estima-
tion in Iran is a fundamental limitation for the formulation of pre-
cise estimates, and creates large-scale uncertainties. In addition, 
the GBD study results are mostly model-driven, but data-driven 
studies are more valuable for making health strategies. The GBD 
VWXG\¿QGLQJVKDYHDOVREHHQFDOFXODWHGDWDnational level, while 
appropriate interventions and resource allocation in every country 
require the determination of the burden of disease and risk factors 
at a sub-national level. Despite the existing limitations, to the best 
of our knowledge, the GBD study LVWKH¿UVWWRHVWLPDWHWKHEXU-
den of drug and alcohol use disorders in Iran. 
The above-mentioned limitations reveal the need to calculate the 
burden of disease, injuries, and risk factors at a sub-national level, 
alongside the national level. Therefore, the burdens of disease and 
risk factor analyses at the provincial or district levels should be 
taken into account. In this regard, the National and Sub-National 
Burden of Disease (NASBOD) study, has been conducted as a 
systematic comprehensive study using a standardized protocol 
of data collection, estimation processes, and advanced statistical 
models to evaluate the burden of disease, injuries, and risk fac-
tors at national and sub-national levels from 1990 to 2013. More 
information is available elsewhere about the details of the NAS-
BOD project.31,32 This study prepares precise data for estimating 
the health status over time in every province or across provinces, 
and could be a major source for evaluating the national and sub-
national health priorities. 
In conclusion, the available evidence leaves no doubt that Ira-
nian men suffer more from the consequences of drug and alcohol 
use disorders compared to women. This issue highlights the need 
to pay more attention to men to mitigate the burden of drug and 
alcohol dependence in Iran. In addition, this would seem to be 
the time to break ‘the drug and alcohol use taboo’ in Iran, inform 
the general population about the consequences of illicit drug and 
alcohol use at a national scale, and look at drug users as patients 
rather than convicts in the country. The results of the present study 
can aid policy makers in enhancing the existing policies towards 
Figure 3. DALYs Rates per 100,000 by Year, Sex, YLLs and YLDs.
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drug and alcohol use disorders and in improving the level of pub-
lic health in Iranian communities. 
Acknowledgments
We would like to thank the Institute for Health Metric and Evalu-
ation (IHME) team for providing the results of the GBD study 
2010. We also thank the Ministry of Health and Medical Educa-
tion of Islamic Republic of Iran, and Setad-e-Ejraie Farmane 
Imam for their kind helps and supports.
Competing interests: None declared 
Authors’ contributions
General designing of paper: Babak Moazen, Mostafa Sho-
koohi, Atefeh Noori, Masoud/RW¿]DGHK
Designing of tables and graphs: Mostafa Shokoohi, Sahar 
Saeedi Moghaddam, Forough Pazhuheian
Writing primary draft: Babak Moazen, Shadi Rahimzadeh, 
6KRKUHK 1DGHULPDJKDP )DULPDK 5H]DHL 0DVRXG /RW¿]DGHK
Mohammad Reza Kazemi
Manuscript revision: Babak Moazen, Shohreh Naderimagham, 
Farimah Rezaei,Hamid Reza Jamshidi, Setareh Rabbani  
References
1. Supic ZT, Petrovic R, Milicevic MS, Trajkovic G, Bukumiric Z. The 
oral health of heroin drug users: case study in Bosnia and Herzegovi-
na. BMC Public Health. 2013; 13(1): 1202.
2. Haritavorn N. Surviving in two worlds: Social and structural violence 
of Thai female injecting drug users. Int J Drug Policy. 2014; 25(1): 
116-23.
3. Nogueira M, Bosch R, Valero S, Gómez-Barros N, Palomar G, Rich-
arte V, et al. Early-age clinical and developmental features associated 
WR6XEVWDQFH8VH'LVRUGHUVLQ$WWHQWLRQ'H¿FLW+\SHUDFWLYLW\'LVRU-
der in Adults. Compr Psychiatry. 2014; 55(3): 639-49. 
4. Li K, Simons-Morton BG, Brooks-Russell A, Ehsani J, Hingson R. 
Drinking and parenting practices as predictors of impaired driving be-
haviors among U.S. Adolescents. J Stud Alcohol Drugs. 2014; 75(1): 
5-15.
5. Ghimire B, Suguimoto SP, Zamani S, Ono-Kihara M, Kihara M. Vul-
nerability to HIV infection among female drug users in Kathmandu 
Valley, Nepal: a cross-sectional study. BMC Public Health. 2013; 
13(1): 1238. 
6. Mirabi P, Yarmohammadi-Vasel M, Moazen B, Sehat M, Rezazadeh 
M, Ahmadi K. Unprotected anal intercourse among Iranian intra-ve-
nous drug users. Front Public Health. 2013; 1: 34.
7. 8QLWHG1DWLRQV2I¿FHRQ'UXJVDQG&ULPH'UXJ7UDI¿FNLQJ$YDLO-
DEOH IURP 85/ KWWSZZZXQRGFRUJXQRGFHQGUXJWUDI¿FNLQJ
index.html.
8. Farhoudian A, Sadeghi M, Khoddami-Vishteh HR, Moazen B, Fekri 
M, Rahimi-Movaghar A. Component analysis of Iranian crack; a 
newly abused narcotic substance in Iran. Iran J Pharm Res. 2014; 13 
(1): 337-44.  
9. Ahmadi K, Rezazade M, Nafarie M, Moazen B, Yarmohmmadi-Vasel 
M, Assari S. Unprotected sex with injecting drug users among Iranian 
female sex workers: Unhide HIV Risk Study. AIDS Res Treat. 2012; 
2012: 651070. 
10. Dana D, Zary N, Peyman A, Behrooz A. Risk prison and hepatitis B 
virus infection among inmates with history of drug injection in Isfa-
han, Iran. 6FLHQWL¿F:RUOG-RXUQDO. 2013; 2013: 735761. 
11. Baheiraei A, Hamzehgardeshi Z, Mohammadi MR, Nedjat S, Mo-
hammadi E. Alcohol and drug use prevalence and factors associated 
with the experience of alcohol use in Iranian adolescents. Iran Red 
Crescent Med J. 2013; 15(3): 212-7. 
12. Afzali S, Saleh A, Seif Rabiei MA, Taheri K. Frequency of alcohol 
DQGVXEVWDQFHDEXVHREVHUYHGLQGULYHUVNLOOHGLQWUDI¿FDFFLGHQWVLQ
Hamadan, Iran. Arch Iran Med. 2013; 16(4): 240-2. 
13. -RGDWL$56KDNXULH6.1D]DUL05DX¿H0%6WXGHQWV¶ DWWLWXGHV
and practices towards drug and alcohol use at Tabriz University of 
Medical Sciences. East Mediterr Health J. 2007; 13(4): 967-71. 
14. Murray CJ, Lopez AD. Measuring the global burden of disease. N 
Engl J Med. 2013; 369(5): 448-57.
15. Wang H, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, Marcus JR, 
/HYLQ5HFWRU$HWDO$JHVSHFL¿FDQGVH[VSHFL¿FPRUWDOLW\LQ
countries, 1970–2010: a systematic  analysis for the Global Burden of 
Disease Study 2010. Lancet. 2012; 380(9859): 2071-94.
16. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, 
et al. A comparative risk assessment of burden of disease and injury 
attributable to 67 risk factors and risk factor clusters in 21 regions, 
1990–2010: a systematic analysis for the Global Burden of Disease 
Study 2010. Lancet. 2012; 380(9859): 2224-60.
17. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et 
al. Global and regional mortality from 235 causes of death for 20 age 
groups in 1990 and 2010: a systematic analysis for the Global Burden 
of Disease Study 2010. Lancet. 2012; 380(9859): 2095-128.
18. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud 
C, Ezzati M, et al. Disability-adjusted life years (DALYs) for 291 dis-
eases and injuries in 21 regions, 1990–2010: a systematic analysis for 
the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 
2197-223.
19. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud 
D, HWDO*%'GHVLJQGH¿QLWLRQVDQGPHWULFVLancet. 2012; 
380(9859): 2063-66.
20. Salomon JA, Vos T, Hogan DR, Gagnon M,  Naghavi M, Mokdad A, 
et al. Common values in assessing health outcomes from disease and 
injury: disability weights measurement study for the Global Burden of 
Disease Study 2010.  Lancet. 2012; 380(9859): 2129-43.
21. Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD, 
et al. Healthy life expectancy for 187 countries, 1990–2010: a system-
atic analysis for the Global Burden Disease Study 2010. Lancet. 2012; 
380(9859): 2144-62.
22. Shield KD, Rehm M, Patra J, Sornpaisarn B, Rehm J. Global and 
&RXQWU\ 6SHFL¿F$GXOW SHU FDSLWD &RQVXPSWLRQ RI$OFRKRO, 2008. 
Sucht. 2011; 57(2): 99-117
23. Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use 
as a risk factor for tuberculosis—a systematic review. BMC Public 
Health. 2008; 8: 289.
24. Samokhvalov AV, Irving H, Mohapatra S, Rehm J. Alcohol consump-
tion, unprovoked seizures, and epilepsy: a systematic review and 
meta-analysis. Epilepsia. 2010; 51(7): 1177-84.
25. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full 
participation in harm reduction programmes is associated with de-
FUHDVHGULVNIRUKXPDQLPPXQRGH¿FLHQF\YLUXVDQGKHSDWLWLV& virus: 
evidence from the Amsterdam Cohort Studies among drug users. Ad-
diction. 2007; 102(9): 1454-62.
26. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course 
of VFKL]RSKUHQLD\HDUIROORZXSDIWHU¿UVWKRVSLWDOL]DWLRQAm J 
Psychiatry. 2010; 167(8): 987-93.
27. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, 
Hall WD, et al. Global burden of disease attributable to illicit drug use 
and dependence: ¿QGLQJVIURPWKH*OREDO%XUGHQRI'LVHDVH6WXG\
2010. Lancet. 2013; 382(9904): 1564-74.
28. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawatt-
ananon Y, Patra J. Global burden of disease and injury and economic 
cost attributable to alcohol use and alcohol-use disorders. Lancet. 
2009; 373(9682): 2223-33. 
29. World Health Organization. Global Burden of Disease, Regional Es-
timates for 2000–2011. Geneva: WHO; 2014. Available from: URL: 
http://www.who.int/healthinfo/global_burden_disease/estimates/en/
index2.html.
30. United Nations 2I¿FHRQ'UXJVDQG&ULPHWorld Drug Report 2013.
Vienna Austria; 2013. Available from: URL: http://www.unodc.org/
unodc/secured/wdr/wdr2013/World_Drug_Report_2013.pdf.
31. 1DVHUEDNKW0'MDODOLQLD6K7D\H¿%*KRODPL0(IWHNKDU$UGDELOL
M, Shariat SV, et al. National and sub-national prevalence, trend, and 
burden of mental disorders and substance abuse in Iran: 1990 – 2013, 
Study Protocol. Arch Iran Med. 2014; 17(3): 182-8.
32. Farzadfar F, Delavari A, Malekzadeh R, Mesdaghinia A, Jamshidi 
+56D\\DUL$HWDO1$6%2'GHVLJQGH¿QLWLRQVDQGPHWULFV
Arch Iran Med. 2014; 17(1): 7-15.
